Minimal Change Disease

Meet the patient

A 4-year-old is brought in by his mother: three days of frothy urine, swollen eyes on waking, and a scrotum so puffy he refuses his trousers. Blood pressure is normal, the urine dipstick reads 4+ protein, and there is no haematuria. This is the textbook first presentation of MCD — and it sets up the central fork of the whole topic.[1]

In a typical child like this one you treat first and biopsy later: in the paediatric setting a renal biopsy is usually not performed if the presentation is typical and the patient responds to oral prednisone, so steroid-sensitive nephrotic syndrome can be considered synonymous with MCD. In an adult with the same numbers you biopsy first, because the chance of FSGS, membranous, or amyloid is high enough to change the plan. Hold that fork and every section below slots into place.[1]

The triad — normal microscopy, no deposits, effaced foot processes

MCD is defined by what is NOT on the slide and by one finding on electron microscopy. Reproduce the triad verbatim — it opens every viva:[1]

• Light microscopy: normal glomeruli — the pathologic hallmark is the absence of visible alterations by light microscopy.
• Immunofluorescence: no immune deposits — a deposit changes the diagnosis.
• Electron microscopy: diffuse effacement of podocyte foot processes — the defining ultrastructural lesion.[1]

The old names tell the same story: nil disease (nothing to see on light microscopy) and lipoid nephrosis (lipid-laden tubular casts). Both describe an absence — which is the whole point of the disease.[1]

Classification — primary, secondary, and the look-alikes

Most MCD is primary and steroid-responsive; the secondary forms are the ones you must not miss, because treating the trigger can remit the kidney. In adults, the history and selected diagnostic studies should rule out important secondary causes, including diabetes mellitus, systemic lupus erythematosus, and medication adverse effects.[11]

[1]

C1q nephropathy and IgM nephropathy

Mesangioproliferative variants with IgM or C1q deposits sit between MCD and FSGS in steroid responsiveness; they are grouped with the podocytopathies and often treated empirically as MCD until the relapse pattern declares itself.[1]

Who gets it, and the secondary-cause screen

MCD is a major cause of idiopathic nephrotic syndrome, accounting for approximately 15 percent of adults with idiopathic nephrotic syndrome and reaching a much higher percentage at younger ages — up to 70–90 percent in children over one year of age.[1] Idiopathic nephrotic syndrome is the most frequent paediatric glomerular disease, affecting from 1.15 to 16.9 per 100,000 children per year globally.[2]

A sizeable minority of adult disease is secondary to something treatable, which is why the drug history, the infection and malignancy screen, and the medication review come before the steroid prescription — medication adverse effects are among the important secondary causes that must be ruled out in adult nephrotic syndrome.[11]

Pathophysiology — immune dysregulation meeting a vulnerable podocyte

MCD is a podocytopathy: the glomeruli look pristine on light microscopy and immunofluorescence, but the foot processes are flattened on EM. The cause is unknown; immunologic dysregulation and modifications of the podocyte are thought to synergize in altering the integrity of the glomerular basement membrane and thereby determining proteinuria. Different subgroups of the disease may recognise different pathogeneses.[1]

[1]

Why no immune deposits? Because this is not an antibody-mediated, immune-complex disease — the injury is functional and cytokine-mediated rather than deposit-forming. Podocytopathies such as MCD and FSGS share common causes and lie along a spectrum: no change in podocyte number in MCD versus podocyte detachment and death in FSGS.[1] That reversibility is the biological basis of the bedside steroid trial.

Clinical presentation — sudden nephrotic syndrome

MCD presents as intense proteinuria leading to oedema and intravascular volume depletion. In children the parents notice periorbital puffiness on waking (misdiagnosed as allergy), then dependent oedema, then scrotal or labial swelling, then ascites. Frothy urine is the cardinal symptom.[1]

In an adult the picture is more indolent and more dangerous. Acute renal failure occurs in a significant number of adult MCD patients — in one referral series it affected 24 of 95 patients — and those patients tended to be older and hypertensive with lower serum albumin and more proteinuria than those without it.[3] Venous thrombosis and hyperlipidaemia are important complications of the nephrotic state in adults, alongside infection and acute kidney injury.[11]

The differential — and the biopsy that settles it

MCD sits in the middle of the nephrotic family, and the biopsy plus the clinical context is what separates it from its siblings. MCD and FSGS are the two faces of the podocytopathy spectrum: hallmark histologic differences distinguish them, yet they share common causes, and classifying them by pathogenesis and treatment response can assist long-term management as an alternative to pure histologic description.[1]

[1]

The bedside discriminator that earns marks: immune-complex stigmata point away from MCD. A deposit on immunofluorescence — full-house lupus, IgA, or subepithedral membranous pattern — changes the diagnosis, because MCD is defined by their absence.[1]

The fork — empirical steroids in the child, biopsy first in the adult

This is the decision the vignette at the top is built around. In a child with a typical first presentation you start oral prednisone at conventional dosing without a biopsy — in the paediatric setting a renal biopsy is usually not performed if the presentation is typical and the patient responds to oral prednisone, because approximately 85–90 percent of children attain complete remission of proteinuria within 4–6 weeks of glucocorticoid treatment.[1][2]

In an adult you biopsy first: renal biopsy is often recommended in adult nephrotic syndrome, and it is most useful where it can guide management — for example in suspected systemic lupus erythematosus or other renal disorders.[11]

Re-biopsy is the answer whenever the disease stops behaving like MCD — an examiner favourite:[1]

• Steroid resistance — forms unresponsive to steroids may subsequently reveal themselves as FSGS, and patients who progressed to ESRD in the adult series were more likely to have FSGS on repeat renal biopsy.[3]
• Any adult with primary nephrotic syndrome, where histology changes the drug.[11]

Investigations — confirm the nephrotic syndrome, then prove MCD on biopsy

First-line is a nephrotic work-up; the biopsy is reserved for the atypical child and the universal adult. In children, nephrotic syndrome is defined by nephrotic-range proteinuria (at or above 40 mg/m²/hour, or a urine protein/creatinine ratio at or above 200 mg/mL, or 3+ protein on urine dipstick), hypoalbuminaemia (albumin under 25 g/L), and oedema.[12]

[12]

The adult work-up is built around excluding secondary causes: the patient history and selected diagnostic studies rule out important secondary causes, including diabetes mellitus, systemic lupus erythematosus, and medication adverse effects, with confirmation of heavy proteinuria and hypoalbuminaemia.[11]

The biopsy findings restate the triad — normal LM, no IF deposits, diffuse foot-process effacement on EM — and when EM is unavailable, an abrupt nephrotic syndrome with a dramatic steroid response supports MCD in the classic case.[1]

Management — support the nephrotic state first

Before any steroid, deal with the complications of the nephrotic state: oedema, thrombosis risk, and infection. For most adult patients, treatment consisting of sodium restriction, fluid restriction, loop diuretics, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy, and careful assessment for possible disease complications is appropriate — despite a lack of evidence-based guidelines.[11]

• Oedema: loop diuretics are the most common supportive medication. Adding albumin to furosemide produces greater urine excretion than furosemide alone (standardised mean difference 0.85, 95 percent CI 0.33 to 1.38), but the current evidence is not sufficient to make definitive conclusions about the routine role of albumin in treating nephrotic oedema — high-quality randomised studies are still needed.[10]
• Thrombosis: venous thrombosis is an important complication of the nephrotic state, but routine prophylactic treatment to prevent infection or thrombosis is not recommended; a nephrologist should be consulted about the use of anticoagulation.[11]
• Infection and acute kidney injury: both are recognised complications; spontaneous acute kidney injury from nephrotic syndrome is rare but can occur as a result of the underlying medical problem.[11]
• Hyperlipidaemia: recognised as an important complication of the nephrotic state and managed as part of the supportive package.[11]

Management — steroids and the ladder

Glucocorticoids are the cornerstone, inducing complete remission of proteinuria within 4–6 weeks in approximately 85–90 percent of children. Among steroid-sensitive children, 70–80 percent will have at least one relapse during follow-up, and up to half will experience frequent relapses or become dependent on glucocorticoids to maintain remission — that is the fork that re-routes the whole pathway.[2]

The steroid regimens — verbatim

Children — current guidelines recommend prednisone 60 mg/m² body surface area per day for the initial therapy of nephrotic syndrome; alternatively, a dosage of 2 mg/kg body weight per day can be used. Note the two are not equivalent for children under 30 kg or doses under 60 mg/day — the weight-based dose runs about 15 percent lower than the surface-area dose.[4]

Adults — first-line therapy is extrapolated largely from paediatric studies and consists of high-dose oral corticosteroids: a conventional regimen is prednisone 1 mg/kg/day (maximum 80 mg/day) for 24 weeks, as used in the control arm of the randomised MSN trial. During 52 weeks of follow-up in that trial, disease relapsed in 23.1 percent of participants who had achieved the primary remission outcome.[5]

Commit the 1 mg/kg per day, maximum 80 mg pair to memory — it is the answer to every first-line adult therapy question.[5]

Disease-course definitions — the concepts that change therapy

[2]

Second-line — the steroid-sparing ladder

Once a patient is frequently relapsing or steroid-dependent, steroid-sparing immunosuppression enters — and no single agent has proved superior.[3]

• Calcineurin inhibitors — compared with prednisolone alone, CNIs with reduced-dose prednisolone or without prednisolone probably make little or no difference to the number achieving complete remission in adult MCD (8 studies, 492 participants: RR 0.99), but may reduce the risk of obesity or Cushing syndrome (RR 0.11) and acne (RR 0.15) — i.e. they are steroid-sparing, not remission-enhancing.[6]
• Mycophenolate — low-dose prednisone plus enteric-coated mycophenolate sodium 720 mg twice daily was not superior to standard high-dose prednisone for inducing complete remission in adult MCD in the MSN randomised trial.[5]
• Rituximab — in children with complicated, frequently relapsing or steroid-dependent disease, a multicentre, double-blind, randomised, placebo-controlled trial showed rituximab is an effective and safe treatment.[8] In adults with frequent-relapsing or steroid-dependent MCD, a meta-analysis of 21 studies found a pooled complete-remission rate of 84.2 percent (91.6 percent in MCD), with 27.4 percent relapsing during follow-up — an effective and relatively safe alternative to displace calcineurin inhibitors or prednisone.[9]

Third-line and beyond — the non-corticosteroid agents

• Non-corticosteroid immunosuppressive medications (including cyclophosphamide) prolong periods of remission in relapsing, steroid-sensitive disease in children, but there is currently no consensus about the most appropriate second-line agent — the choice among them balances their significant potential adverse effects against cumulative steroid toxicity.[7]
• Anti-CD20 antibodies beyond rituximab — recent therapeutic advances with anti-CD20 antibodies have provided long-term remission off-therapy in MCD and suggest new hypotheses for disease pathogenesis.[1]

Supportive care throughout

• Loop diuretics with salt and fluid restriction form the supportive backbone for oedema in adults.[11]
• ACE inhibitor or ARB therapy is part of appropriate treatment for most patients with nephrotic syndrome.[11]
• Anticoagulation is not routine: consult nephrology about its use rather than starting it reflexively.[11]

The treatment ladder — RAINBOW

[11]

The algorithm in one breath: diagnose (biopsy in adults, empirical trial in children) → start high-dose steroids → expect remission within 4–6 weeks in children → relapsers reinstate steroids then escalate to steroid-sparing agents, and resistant patients are re-biopsied, because steroid-unresponsive disease may reveal itself as FSGS.[1][2]

The scenarios that change the plan

Adult-onset MCD

Biopsy before treatment in every case. Adult MCD runs a rougher course than the paediatric disease: in a 95-patient referral series more than a quarter of patients were steroid resistant, at least one relapse occurred in 73 percent, 28 percent were frequently relapsing, acute renal failure occurred in 24 patients, and only four patients progressed to ESRD — those ESRD patients were less likely to have responded to steroids and more likely to have FSGS on repeat renal biopsy.[3]

Steroid-dependent and frequently relapsing MCD

Among children who are steroid sensitive, 70–80 percent will have at least one relapse during follow-up and up to half will become frequent relapsers or steroid dependent.[2] Management escalates to steroid-sparing agents — non-corticosteroid immunosuppressive medications prolong periods of remission, with no consensus on the single best agent — and rituximab is supported by a randomised placebo-controlled trial in children and a meta-analysis in adults.[7][8][9]

Steroid-resistant MCD

Failure to remit on full-dose steroids triggers the triumvirate work-up: re-biopsy to exclude FSGS — forms of MCD unresponsive to steroids may subsequently reveal themselves as FSGS, and repeat-biopsy FSGS defined the patients who progressed in the adult series — plus a search for secondary causes and specialist input on second-line agents.[1][3]

Complications — infection, thrombosis, AKI

Infection, venous thrombosis, and hyperlipidaemia are the important complications of the nephrotic state, with acute kidney injury a rarer but recognised event. Spontaneous acute kidney injury from nephrotic syndrome is rare but can occur as a result of the underlying medical problem.[11]

[11]

Acute renal failure occurred in 24 of 95 adults with MCD in the referral series; those patients tended to be older and hypertensive with lower serum albumin and more proteinuria, and at follow-up they had higher serum creatinine than those without — acute renal failure in adult MCD may leave residual renal dysfunction.[3] Steroid-related morbidity is the other price of the ladder: patients with relapsing disease continue to experience a high prevalence of steroid-related morbidity, which is the explicit rationale for steroid-sparing strategies.[2]

Prognosis — excellent if steroid-sensitive

Children do well. Approximately 85–90 percent attain complete remission of proteinuria within 4–6 weeks of glucocorticoids; among steroid-sensitive patients, 70–80 percent will have at least one relapse during follow-up and up to half will experience frequent relapses or become steroid dependent.[2] Forms of MCD that respond to steroids usually do not lead to chronic renal damage, whereas forms that are unresponsive to steroids may subsequently reveal themselves as FSGS — that is the single most important prognostic fork.[1]

Adults do less well. More than a quarter of patients in the referral series were steroid resistant; at least one relapse occurred in 73 percent and 28 percent were frequently relapsing, with a significant proportion of frequently relapsing patients becoming steroid dependent. No single second-line agent proved superior — but remissions with second-line agents were more likely in steroid-dependent than steroid-resistant patients, and few patients progressed to ESRD.[3]

Evidence and guidelines

KDIGO anchors practice. The KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases covers minimal change disease among the glomerular diseases and frames the steroid-first, biopsy-directed approach.[13]

IPNA anchors paediatric practice. The International Pediatric Nephrology Association convened an expert team to develop comprehensive, evidence-based clinical practice recommendations for children with steroid-sensitive nephrotic syndrome, graded across 12 PICO questions after systematic literature review — with new treatment-outcome definitions to guide when to change therapy.[2] Cochrane reviews confirm that non-corticosteroid immunosuppressive medications prolong remission in relapsing steroid-sensitive children (no single agent is the consensus choice)[7], that calcineurin inhibitors spare steroid toxicity in adults without adding remission benefit over prednisolone[6], and that randomised evidence supports rituximab in complicated, frequently relapsing childhood disease.[8]

Exam pearls — the ten that come up every year

• Most common cause of nephrotic syndrome in children — up to 70–90 percent of cases in children over one year; about 10–15 percent of adult primary nephrotic syndrome.[1]
• The defining triad — normal light microscopy, no IF deposits, diffuse foot-process effacement on EM.[1]
• Empirical steroid trial in the typical child — biopsy usually not performed if presentation is typical and the patient responds to oral prednisone; biopsy is standard in adults.[1]
• Time to response — complete remission within 4–6 weeks of glucocorticoids in 85–90 percent of children; non-response is the pivot that re-directs management.[2]
• Paediatric dosing — guidelines recommend prednisone 60 mg/m²/day, alternatively 2 mg/kg/day; the two are not equivalent under 30 kg.[4]
• Adult dosing — conventional high-dose prednisone 1 mg/kg/day (maximum 80 mg/day).[5]
• Secondary causes to exclude in adults — diabetes mellitus, systemic lupus erythematosus, and medication adverse effects.[11]
• Steroid-resistant MCD needs re-biopsy — steroid-unresponsive disease may subsequently reveal itself as FSGS; ESRD progressors in the adult series had FSGS on repeat biopsy.[1][3]
• Complications — infection, venous thrombosis, hyperlipidaemia, and acute kidney injury dominate; routine prophylaxis against infection or thrombosis is not recommended.[11]
• Rituximab — randomised, placebo-controlled evidence of efficacy and safety in complicated, frequently relapsing childhood disease; high complete-remission rates in adult meta-analysis.[8][9]

The mantra, and the honesty line

The mantra: steroids first, biopsy the atypical and the resistant, spare the steroid-toxic patient.[1]

[1] [4] [5]

Ward-round test — three stems, thirty seconds each

Stem 1 — the 4-year-old from the vignette (answer)

The 4-year-old with three days of frothy urine, periorbital and scrotal oedema, a blood pressure of 90/60, and 4+ proteinuria with no haematuria. What is the next step, and do you biopsy? Model: This is a typical first presentation of MCD in a child. Start guideline-dose prednisone — 60 mg/m²/day, or alternatively 2 mg/kg/day — without a biopsy. Approximately 85–90 percent of children attain complete remission of proteinuria within 4–6 weeks of glucocorticoids; reserve biopsy for the atypical or the steroid-resistant.[1][2][4]

Stem 2 — the adult who has not remitted (answer)

A 35-year-old with biopsy-proven MCD has completed a full conventional course of prednisone 1 mg/kg/day (maximum 80 mg/day) and is still nephrotic. What is the next move? Model: This is now steroid-resistant disease. The single most important step is to re-biopsy and review the histology for FSGS — forms of MCD unresponsive to steroids may subsequently reveal themselves as FSGS, and in the adult series the patients who progressed to ESRD were more likely to have FSGS on repeat renal biopsy. Second-line steroid-sparing options include calcineurin inhibitors, which spare steroid toxicity, and rituximab, with randomised or meta-analytic evidence in relapsing disease.[1][3][6]

Stem 3 — sudden flank pain and haematuria (answer)

A 50-year-old with active nephrotic MCD suddenly develops left flank pain, macroscopic haematuria, and a falling eGFR. What happened, and what do you do in the next 30 minutes? Model: This is renal vein thrombosis until proven otherwise — venous thrombosis is an important complication of nephrotic syndrome. Confirm with appropriate imaging and involve nephrology urgently about anticoagulation; routine prophylaxis is not recommended, but an established clot in a nephrotic patient is a treatment decision to make with the specialists, without delay.[11]

References

1. [1]Vivarelli M, Massella L, Ruggiero B, et al. Minimal Change Disease Clin J Am Soc Nephrol, 2017.PMID 27940460
2. [2]Trautmann A, Boyer O, Hodson E, et al. IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome Pediatr Nephrol, 2023.PMID 36269406
3. [3]Waldman M, Crew RJ, Valeri A, et al. Adult minimal-change disease: clinical characteristics, treatment, and outcomes Clin J Am Soc Nephrol, 2007.PMID 17699450
4. [4]Feber J, Al-Matrafi J, Farhadi E, et al. Prednisone dosing per body weight or body surface area in children with nephrotic syndrome: is it equivalent? Pediatr Nephrol, 2009.PMID 19165504
5. [5]Rémy P, Audard V, Natella PA, et al. An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study) Kidney Int, 2018.PMID 30385039
6. [6]Azukaitis K, Palmer SC, Strippoli GF, et al. Interventions for minimal change disease in adults with nephrotic syndrome Cochrane Database Syst Rev, 2022.PMID 35230699
7. [7]Larkins NG, Liu ID, Willis NS, et al. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children Cochrane Database Syst Rev, 2020.PMID 32297308
8. [8]Iijima K, Sako M, Nozu K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome Lancet, 2014.PMID 24965823
9. [9]Xue C, Yang B, Xu J, et al. Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis Clin Kidney J, 2021.PMID 34094516
10. [10]Hedin E, Bijelić V, Barrowman N, et al. Furosemide and albumin for the treatment of nephrotic edema: a systematic review Pediatr Nephrol, 2022.PMID 35239032
11. [11]Kodner C. Diagnosis and Management of Nephrotic Syndrome in Adults Am Fam Physician, 2016.PMID 26977832
12. [12]Downie ML, Gallibois C, Parekh RS, et al. Nephrotic syndrome in infants and children: pathophysiology and management Paediatr Int Child Health, 2017.PMID 28914167
13. [13]Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases Kidney Int, 2021.PMID 34556256